CDKN2A/p16INK4a antibody | knockout validation | Abcam ab108349

This is a knockout-validated antibody summary, based on the publication "Identification of CD24 as a potential diagnostic and therapeutic target for malignant pleural mesothelioma", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

CDKN2A/p16INK4a antibody | knockout validation | Abcam ab108349 figure 1
Figure 1. Independent NF2-knockout clones (NF2-KO#1 and #2), p16-knockout clones (p16-KO#1 and #2), and NF2/p16-DKO clones (DKO#1 and #2) were established. NF2 and p16/14 protein expression was determined by western blot analysis. GAPDH was used as an internal standard. From [1].
Antibody information

Rabbit monoclonal IgG

Company: Abcam

Antibody: CDKN2A/p16INK4a

Catalog number: ab108349

Summary: Rabbit monoclonal antibody against a synthetic peptide of CDKN2A/p16INK4a. Reacts with human. Suitable for western blot, immunoprecipitation, immunohistochemistry (paraffin), immunocytochemistry/immunofluorescence, and flow cytometry (intra).

Validation Method

Western blot

Sample

WT and p16-KO MeT-5A and HOMC-B1 human mesothelial cell lines.

Primary incubation

1:2,000 dilution.

Secondary incubation

1:4,000 dilution goat anti-rabbit IgG-HRP (#7074, CST).

Detection

Immuno Star LD (Wako Pure Chemical Industries, Ltd, Osaka, Japan) in conjunction with a LAS-4000 image analyzer (GE Healthcare, Tokyo, Japan).

References
  1. Karnan S, Ota A, Murakami H, Rahman M, Hasan M, Wahiduzzaman M, et al. Identification of CD24 as a potential diagnostic and therapeutic target for malignant pleural mesothelioma. Cell Death Discov. 2020;6:127 pubmed publisher